Health synthetic data: higher dimensionality tests, EU governance push, DNA storage, and longitudinal oncology

New research in JAMIA suggests adding adjunct variables in high-dimensional medical synthetic data generation can improve utility and replicability without a clear increase in measured membership disclosure risk. In parallel, EU stakeholders (via the SYNTHIA project) are pushing synthetic data as a practical way through GDPR constraints—provided validation for clinical validity, utility, and privacy is rigorous. Separate developments highlight continued interest in synthetic DNA data storage and longitudinal synthetic data for oncology research.